Communications technology world-leader Sepura was last night crowned Business of the Year at a glittering Business Weekly Awards ceremony at Queens’ College, Cambridge.

Some 200 leading executives from the East of England, the UK and internationally saw COO Paul Watson lift a title Sepura has coveted for a number of years.

Sepura was the reigning International Trade Champion but a phenomenal year of growth nudged them up that extra notch to join a stunning hall of fame – companies that have graced a world stage over the 26 years of the competition.

Other major winners were Horizon Discovery (Cambridge Torchbearer); Marshall Aerospace & Defence Group (Engineering Excellence); Cambridge Commodities (International Trade); Darktrace (Disruptive Technology); PragmatIC (Startup of the Year); Healx (Cambridge Graduate Business of the Year);  Owlstone Medical (Life Science Innovation); ARM (Kate Gross Prize for Social Enterprise); Jelena Aleksic (Woman Entrepreneur of the Year).

Warren East, chief executive of engineering giant Rolls-Royce and formerly CEO at ARM, presented the prizes. He was a guest speaker along with Cambridge entrepreneur Sherry Coutu, founder of the Scale-up Institute. Sponsors of the Awards are Mills & Reeve, Barclays, UKTI, AstraZeneca, MedImmune, Cambridge Judge Business School, PwC, TTP, St Johns Innovation Centre and Bailey Fisher.

Kevin Calder of Mills & Reeve, explaining why Sepura won, said: “FY15 was Sepura’s third consecutive year of double-digit revenue growth and the fourth consecutive year of double-digit growth in operating profits.

“This trend has continued into FY16, with adjusted operating profits up 170 per cent in the first six months. In the last year Sepura has invested some €17m on R & D and won its largest ever contract – a €35m deal to supply Saudi Arabia with c.100,000 radios. It has made transformational acquisitions; opened up the US market and increased its share price six fold over the last five years – by 25 per cent during 2015 alone.

“Offered the chance to relocate overseas it chose to build a new HQ in Cambridge. And in the process Sepura has transformed from a TETRA devices supplier to a geographically and technologically diverse critical communications solutions supplier with new turnkey products, massive global clients and the world at its feet.”

Horizon Discovery, the Cambridge Torchbearer winner, won Business of the Year last year and came close again this time. Announcing the Torchbearer success, David Gill of St John’s Innovation Centre said: “The first tranche of a triple play by Horizon testifies to their intention to change the game in matching personalised medicines to an individual’s DNA.

“We have just seen the first of the company’s game-changing initiatives, a new joint venture company called Avvinity formed to leverage technology invented by a Nobel Laureate that will fight killer cancers on a fresh front.

“Using vastly differentiated technology, Avvinity promises to discover and develop novel immuno-oncology therapeutics for solid tumours and leukaemias – and there is much more to come from the Horizon stable as it takes the search for personalised medicines to unparallelled heights.

Cambridge Commodities won a closely contested International Trade Award and UKTI’s Thinley Topden said: “Cambridge Commodities has experienced extraordinary and rapid growth of international sales, which resulted in the company being ranked 36th in the Sunday Times International Track 200 League. 

“It posted annual international sales growth from £300k in 2011 to surpass £7 million in 2015. Cambridge Commodities supplies nutritional ingredients to the sports, health food and pet nutrition sectors worldwide, has just moved into brand new, purpose-built premises to accommodate further expansion and is said to be on the cusp of a deal with a globally-acclaimed client that will open up more business in the US, Europe and Asia.”

Owlstone Medical headed off fierce competition to take the AstraZeneca/MedImmune Life Science Innovation Award. Jane Osbourn of MedImmune, said: “Owlstone’s newly-formed medical division has invented a breath test to provide much earlier diagnosis of cancer, asthma and other diseases and conditions. We were impressed by the potential of the technology to save the NHS millions, slash hospital admissions and – most importantly because of swifter diagnosis – to save lives.”

Marshall Aerospace & Defence Group won the Engineering Excellence Award. David Newble of TTP Labtech said: “Marshall Aerospace & Defence Group, with Rolls-Royce and Lockheed Martin, recently won a £369 million MoD contact to support the RAF C-130 Hercules transport fleet until 2022, underpinning 1,000 jobs. 

“It supports civil and military projects globally, supplying the most sophisticated field hospital in NATO and supporting 12 Air Forces around the world. The company reports a 68 per cent growth in export business.”

ARM won the Kate Gross Prize for Social Enterprise: Ann fisher of Bailey Fisher explained: “Talking Book was developed in 2007 between ARM, Literacy Bridge and UNICEF to give people without literacy skills access to audio recordings of interviews, songs, and dramas that address life-saving health and agriculture advice.

“Survival rates of mothers giving birth, and their babies, is rising; so are crop yields. Launched in Ghana the venture is being rolled out to other parts of Africa and hopefully further afield in the not too distant future.”

Healx won the Judge Business School Cambridge Graduate Business of the Year accolade. Hanadi Jabado of Judge, said: “Healx, which was founded to match potential new cures to the world’s rarest diseases, has developed a novel treatment allocation method allowing prediction of drug response.
 
“It is based on genomic signature matching between an individual patient and a drug and has the potential to revolutionise personalised medicine to improve patient outcomes and eliminate costly drug wastage in hospitals and throughout the NHS. It has the potential to help millions of people worldwide in an area of vast unmet need.”

Her Judge Business School colleague, Sucheta Nadkarni, announced Jelena Aleksic of GeneAdviser as winner of the inaugural Woman entrepreneur of the Year Award. she said: ““This was an extremely close run affair but we decided on Jelena for a number of reasons, not least market validity and potential healthcare impact.

“Jelena founded and has grown GeneAdviser as an online marketplace for clinical genetic testing –making it easier for doctors to find and order lifesaving tests from accredited laboratories.

“In just one year, she has secured a flagship NHS lab as a customer, surveyed 1000+ clinicians and attracted interest from clinicians across Europe as well as leading life sciences investors. GeneAdviser addresses a great need for accessible genetic testing and will significantly impact the lives of potentially millions of patients globally with rare disease, cancer and neurological conditions.”

PragmatIC Printing was a worthy winner of the Startup of the Year Award, as Adrian Bennett of PwC explained: “PragmatIC is a world leader in ultra low cost flexible electronics, enabling the potential for trillions of smart objects that can sense and communicate with their environment. 

“Its technology enables integrated circuits thinner than a human hair to be easily embedded in any surface, introducing interactivity into a wide range of everyday items.

“At a fraction of the price of conventional silicon chips, PragmatIC’s products enable a vast range of new applications: from intelligent packaging of fast-moving consumer goods, to wireless traceability of documents for security and identification.”

Duncan McCunn of Barclays introduced the Disruptive Technology category and explained why Darktrace was such a worthy winner. He said: “Darktrace has invented digital antibodies that enable a machine to automatically fight off cyber attacks on a network’s immune system. 

“Up to now it has helped governments and corporations identify areas of their systems vulnerable to attack and alert them to raids. Now it has taken the enterprise immunity technology a vital stage further with a new product called Antigena that enables networks to self-defend.

“Darktrace hails Antigena as a key weapon in a new cyber world war where machines fight machines and sophisticated attackers are mobilised.”

SyndicateRoom in the Cambridge technology cluster has become the first crowdfunding platform to join the public markets.

It has been granted intermediary status by the London Stock Exchange, allowing crowdfunding investors to participate in IPOs and placings on the UK’s main market and AIM.

CEO Goncalo de Vasconcelos has hailed the coup as “a complete game-changer to the crowdfunding  industry and to the City. The City of London is now headquartered right here in Cambridge.”

The step change came with the company’s approved intermediary status for the £200 million IPO of HealthCare Royalty Trust Plc.

SyndicateRoom is the only alternative finance company to provide its members with direct access to public and private equity markets – helping their investor base diversify their exposure to different asset classes through one platform.

A broad spectrum of equity opportunities will be available to SyndicateRoom members – from early-stage crowdfunding rounds through to high-growth IPOs, pre-IPOs and discounted placings encouraging greater investor loyalty.  SyndicateRoom members will now be able to participate across the entire funding journey of growth businesses.

SyndicateRoom has been recognised by AltFi as among the best platforms for managing risk and safeguarding investors. SyndicateRoom has undertaken over 70 capital raises through the platform since it was founded in 2013.

The launch of SyndicateRoom’s public equity capability means individual investors will be placed in the same position as professionals, with the ability to participate in the IPO market and the opportunity to benefit from the same discounts for new equity issues.

Discounted placings are typically only offered to institutional investors. Over the past two years, over £16.5 billion was raised on the London Stock Exchange via placings and IPOs, with an average 10 per cent discount given.

That means £1.65bn of value has been given to the traditional City of London investment community. SyndicateRoom seeks to spread this benefit to a far wider range of investors and believes there is strong appetite for investment among individuals considered too small to be embraced by the advisor community.

Twelve million individuals in the UK population are estimated to hold individual company shares but over three-quarters of those did not buy into public equity in the last year – so SyndicateRoom will be providing the London exchange with an important and a valuable new source of retail investor demand.

SyndicateRoom has a strong track record in healthcare investments: In August 2014, Oval Medical Technologies successfully raised £1,118,647 through the SyndicateRoom platform, to manufacture a pilot tool for its drug-device combination study.

In December 2014, Lightpoint Medical raised £989,998 through SyndicateRoom to bring its two lead imaging products to the EU and US markets.

Fertility Focus’s first funding round in May 2014 raised £880,500 through SyndicateRoom to invest in marketing for its fertility monitor; and in June 2014, Time for Medicine realised £330k to further expand its offering, using cloud technology to bring specialist medical diagnoses to patients in primary care or at home.

Last November, Check4Cancer garnered £550,543 through SyndicateRoom to drive top line growth through brand building and customer acquisition and Axol Bioscience, the human cell culture pioneer based in Cambridge bust the £1m barrier in a recent SyndicateRoom fundraising.
de Vasconcelos said: “SyndicateRoom has already built a large member base of online crowdfunding investors, helping to create a new equity-owning class – the mass affluent.

“We are now seeking to democratise access to the public market, widening the reach of IPO discounts and putting the public back into IPO.
“SyndicateRoom’s move into the public equity market is another step in the evolution of the London Stock Exchange providing capital to growth companies, now with greater participation from individual investors.”

David Brown, stockmarket investor and SyndicateRoom member, said the development was a huge development. “I’ve been investing for more than 25 years on the stock exchange and 15 years as a business angel and am incredibly excited about the prospect of having access to IPOs and private placings on a level playing field with institutional investors. It’s fantastic to see SyndicateRoom leading the way, once again.”

And serial entrepreneur Jonathan Milner, co-founder and deputy chairman of Abcam plc added: “I wish this model had existed back when I listed Abcam. SyndicateRoom will enable a much larger base of retail shareholders for companies, which in turn will increase liquidity and stability. I believe this is a very positive shift for the industry.”
 

Cambridge cyber security pioneer Darktrace has invented digital antibodies that enable a machine to automatically fight off cyber attacks on a network’s immune system.

Up to now the UK company has helped governments and corporations identify areas of their systems vulnerable to attack and alert them to raids. Now it has taken the enterprise immunity technology a vital stage further with a new product called Antigena that enables networks to self-defend.

Darktrace is the first company in the world to arm the defenders with proven machine learning and mathematics that work without any prior knowledge of attacks, rules or signatures.

Darktrace hails Antigena as a key weapon in a new cyber world war where machines fight machines and sophisticated attackers are mobilised. 
With Antigena, Darktrace now spots and inoculates against unknown threats, as they germinate within organisations in real time.

Nicole Eagan (pictured), CEO, Darktrace said: “The battlefield is the corporate network – we cannot fight the battle on the border anymore. We are living through a new era of threat which is relentless and pernicious – and it’s inside our networks now. Today, we have arrived at new detection that reacts faster than any security team can.” 

With over 200 customers and 20 global locations, Darktrace is the fastest growing cyber company in the world and recognised by the World Economic Forum. Its technology is powered by unrivalled machine learning developed by renowned mathematicians within Cambridge University.

Public sector contracts can be very lucrative for your organisation, however bid writing and tendering can be a challenge.
 
This workshop will show you how to avoid the common mistakes, implement top tips and use best practice when bidding for contracts.
 
Delivered by Enterprise Europe Network, our expert advisers will help you to beat the bureaucracy and make sense of the jargon, from PQQs (Pre Qualification Questionnaire), to ITT (Invitation to Tender) and Tender Documents.
 
The seminar will be led by Toni Saraiva who has delivered over 250 procurement workshops, in the UK, Europe, Canada and Israel to help SMEs better understand how to bid for public contracts.
 
Why attend?

• Would you like to discover if bidding for public procurement would be a good idea for your business?
• By attending our workshop you will benefit from expert advice, case studies, group work and most importantly,working on a tender that you could bid for.
• Find out about the latest changes to public procurement legislation and procedures designed to make tendering easier for SMEs.
• We will provide some practical suggestions on how to sell to the public sector. Find out if your business is ready to tender and what resources you may need.